Phase I Study of Neoadjuvant GMCI plus Immune Checkpoint Inhibitor Combined with Standard of Care for Newly Diagnosed High-Grade Gliomas (IRB00172749)
Contact: Michaella Iacoboni (msheeh13@jhmi.edu)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test the safety of a treatment called Gene Mediated Cytotoxic Immunotherapy (GMCI) plus the anticancer drug nivolumab, in combination with standard radiation therapy (RT) + temozolomide (TMZ).
Eligibility Criteria: Adults with a newly diagnosed brain tumor called high grade glioma
A Phase I Trial of anti-Tim-3 in combination with anti-PD-1 and SRS in Recurrent GBM (IRB00104226)
Contact: Kelly Szajna, RN, BSN (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To find out if two study drugs PDR001 and MBG453 are safe to give with stereotactic radiosurgery (SRS).
Eligibility Criteria: Adults with recurrent glioblastoma (GBM)
Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas (IRB00151324)
Contact: Amber Michalik (410-502-0756)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test any good and bad effects of the study drugs called vemurafenib and cobimetinib
Eligibility Criteria: Adults with a craniopharyngioma which has recurred (came back).
Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine (IRB00086553)
Contact: Whitney Isennock (410-955-7008) or Kelly Szajna (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using stereotactic radiosurgery (SRS) and Nivolumab together to treat melanoma that has spread to the brain or spine.
Eligibility Criteria: Adults with newly identified brain OR spinal metastases
Stereotactic Radiosurgery with Nivolumab in Subjects with Chordoma (IRB00117650)
Contact: Whitney Isennock (410-955-7008) or Kelly Szajna (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using Nivolumab alone or Nivolumab and stereotactic radiosurgery (SRS) together to treat advanced chordomas.
Eligibility Criteria: Advanced/recurrent Chordoma in 1 or more site